Teva Pharmaceutical Industries

C4 Therapeutics Announces the Additions of William McKee as Chief Financial Officer and Jolie M. Siegel as Chief Legal Officer

Retrieved on: 
Wednesday, July 15, 2020
Biotechnology, Pharmaceutical, Health, Oncology, Pharmaceutical companies, Science and technology in Israel, Teva Pharmaceutical Industries, Life sciences, William McKee, Teva, Industries

C4 Therapeutics, Inc. (C4T), a biotechnology company pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation, today announced the addition of William McKee and Jolie M. Siegel to its leadership team as Chief Financial Officer and Chief Legal Officer, respectively.

Key Points: 
  • C4 Therapeutics, Inc. (C4T), a biotechnology company pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation, today announced the addition of William McKee and Jolie M. Siegel to its leadership team as Chief Financial Officer and Chief Legal Officer, respectively.
  • Mr. McKee currently also serves as Chief Executive Officer of MBJC Associates, LLC, a business consulting firm serving the pharmaceutical and biotech industry.
  • Mr. McKee was also Executive Vice President and Chief Financial Officer of Barr from 1996 until its acquisition by Teva.
  • At Neon, Ms. Siegel was responsible for overseeing all aspects of the legal, intellectual property, compliance and corporate governance functions for the company.

Phathom Pharmaceuticals Announces Appointment of Todd Branning as Chief Financial Officer

Retrieved on: 
Monday, July 13, 2020
Pharmaceutical companies, Amneal Pharmaceuticals, Teva Pharmaceutical Industries, Industries, Life sciences

FLORHAM PARK, N.J., July 13, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc.(Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it has appointed Todd Branning as Chief Financial Officer.

Key Points: 
  • FLORHAM PARK, N.J., July 13, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc.(Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it has appointed Todd Branning as Chief Financial Officer.
  • Mr. Branning was most recently with Amneal Pharmaceuticals, Inc. (NYSE: AMRX) where he served as Senior Vice President and Chief Financial Officer.
  • I am delighted to welcome Todd to Phathom and to have him join our executive leadership team.
  • Prior to Amneal Pharmaceuticals, he served as Senior Vice President, Chief Financial Officer for Teva Pharmaceuticals' (NYSE: TEVA) Global Generic Medicines division.

Teva Announces Availability of ProAir® Digihaler® (albuterol sulfate 117 mcg) Inhalation Powder for Patients with Asthma and COPD

Retrieved on: 
Monday, July 13, 2020
Data management, Technology, Other Health, Health, Pharmaceutical, Other Science, Other Technology, Research, Software, Mobile, Wireless, Science, Science and technology in Israel, Teva Pharmaceutical Industries, Life sciences, Articles, Health, Teva, Tel Aviv Stock Exchange, Pharmaceutical industry

Stop using ArmonAir Digihaler and call your healthcare provider or get emergency medical care if you get any of the following symptoms of a serious allergic reaction:

Key Points: 
  • Stop using ArmonAir Digihaler and call your healthcare provider or get emergency medical care if you get any of the following symptoms of a serious allergic reaction:
    slowed growth in children.
  • You should have regular eye exams while using ArmonAir Digihaler.
  • If this occurs, stop using ArmonAir Digihaler and call your healthcare provider.
  • Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve peoples lives for more than a century.

Teva to Host Conference Call to Discuss Second Quarter 2020 Financial Results at 8 a.m. ET on August 5, 2020

Retrieved on: 
Thursday, July 9, 2020
Professional services, Health, Finance, Clinical trials, Pharmaceutical, Biotechnology, Science and technology in Israel, Teva Pharmaceutical Industries, Teva, Tel Aviv Stock Exchange, Economy of Israel, Life sciences, Industries

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter financial results on Wednesday August 5, 2020 at 7:00 a.m.

Key Points: 
  • Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter financial results on Wednesday August 5, 2020 at 7:00 a.m.
  • Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m.
  • Please log in at least 10 minutes prior to the conference call in order to download the applicable audio software.
  • Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve peoples lives for more than a century.

Cara Therapeutics Expands Board of Directors with Appointment of Susan Shiff, Ph.D., M.B.A.

Retrieved on: 
Tuesday, June 30, 2020
Health, Articles, Life sciences, Science and technology in Israel, Teva Pharmaceutical Industries, Pharmaceutical industry

Her insights and skillset will be valuable resources as we develop and implement evidence-based medicine, patient access and pricing strategies across the KORSUVA development pipeline.

Key Points: 
  • Her insights and skillset will be valuable resources as we develop and implement evidence-based medicine, patient access and pricing strategies across the KORSUVA development pipeline.
  • I look forward to working with the Cara team to optimize commercialization strategies for all ongoing development programs.
  • Before joining Merck, she served as Vice President of Global Health Economics, Data Sciences and Evidence-Based Medicine at Teva Pharmaceuticals.
  • All forward-looking statements contained in this press release speak only as of the date on which they were made.

Insights & Forecast with Potential Impact of COVID-19 - Alcoholic Hepatitis Treatment Market 2020-2024 | Increasing Consumption Of Alcohol to Boost Growth | Technavio

Retrieved on: 
Wednesday, June 24, 2020
Infectious diseases, Pharmaceutical, Health, Life sciences, Pharmaceutical companies, Companies, RTT, Specialty drugs, Hepatitis, Sanofi, Teva Pharmaceutical Industries, Gilead Sciences, Pharmaceutical industry, Novartis, Cadila Healthcare

Our alcoholic hepatitis treatment market report covers the following areas:

Key Points: 
  • Our alcoholic hepatitis treatment market report covers the following areas:
    This study identifies the availability of prognostic models for alcoholic hepatitis as one of the prime reasons driving the alcoholic hepatitis treatment market growth during the next few years.
  • We provide a detailed analysis of around 25 vendors operating in the alcoholic hepatitis treatment market, including some of the vendors such as Cadila Healthcare Ltd., Gilead Sciences Inc., Johnson & Johnson, Mylan NV, Novartis AG, Sanofi, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., and Teva Pharmaceutical Industries Ltd.
  • Backed with competitive intelligence and benchmarking, our research reports on the alcoholic hepatitis treatment market are designed to provide entry support, customer profile and M&As as well as go-to-market strategy support.
  • Register for a free trial today and gain instant access to 17,000+ market research reports.

Nasal Drug Delivery Devices Market Size to Exceed US$ 78.3 Bn by 2027

Retrieved on: 
Tuesday, June 16, 2020
Articles, Health, Companies, Companies based in Ahmedabad, Science and technology in Israel, Teva Pharmaceutical Industries, Pfizer, Pharmaceutical industry in India, AstraZeneca, Pharmaceutical industry in China, Cadila Pharmaceuticals, Pharmaceutical industry

The global nasal drug delivery devices market size to exceed US$ 78.3 Bn by 2027 and anticipated to grow at a CAGR of around 7% from 2020 to 2027.

Key Points: 
  • The global nasal drug delivery devices market size to exceed US$ 78.3 Bn by 2027 and anticipated to grow at a CAGR of around 7% from 2020 to 2027.
  • Advancements in alternative drug delivery system, coupled with availability of advanced infrastructure in order to adopt the advanced devices is supporting the growth of target market in this region.
  • Rising geriatric population in developed and developing countries with various old age associated problems, coupled with increasing demand for minimally invasive drug delivery system are some major factors expected to drive the growth of the global nasal drug delivery devices market.
  • Players operating in the global nasal drug delivery devices market are Consort Medical plc., Vectura Group plc., 3M, Nemera, Aptar Group Inc., H&T Presspart Manufacturing Ltd., Teva Pharmaceutical Ltd., Gofire Inc., AstraZeneca, Pfizer, Inc., and Cadila Pharmaceuticals.

Leading Pharma Packaging Companies Commit to Supply for COVID-19 Fight

Retrieved on: 
Tuesday, June 16, 2020
Health, Articles, Life sciences, Stevanato Group, Pharmaceutical industry, Pharma, Teva Pharmaceutical Industries, Pharmaceuticals policy

Also, the companies will make every effort to support the pharma industry's priorities for overall medication supply in addition to COVID-19 drugs.

Key Points: 
  • Also, the companies will make every effort to support the pharma industry's priorities for overall medication supply in addition to COVID-19 drugs.
  • They are making the statement to provide confidence in the global pharmaceutical supply chain in times of uncertainty.
  • "We stand ready to support the pharmaceutical companies in thefight against the pandemic," said Dr. Frank Heinricht, Chairman of SCHOTT's Management Board.
  • Established in 1949, Stevanato Group is the world's largest, privately-owned designer and producer of glass primary packaging for the pharmaceutical industry.

Teva to Present New Data on AJOVY® (fremanezumab-vfrm) Injection Open-Label Extension Study at American Headache Society Annual Meeting

Retrieved on: 
Monday, June 15, 2020
Biotechnology, Pharmaceutical, Health, Science and technology in Israel, Teva Pharmaceutical Industries, Fremanezumab, Migraine, Teva, Life sciences, Clinical medicine, Industries, Headaches, AJOVY® (fremanezumab-vfrm) injection, Teva

Teva Pharmaceuticals USA, Inc., an affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced 24 abstracts featuring data on AJOVY (fremanezumab-vfrm) injection will be presented at the American Headache Society (AHS) Virtual Annual Scientific Meeting which began June 13.

Key Points: 
  • Teva Pharmaceuticals USA, Inc., an affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced 24 abstracts featuring data on AJOVY (fremanezumab-vfrm) injection will be presented at the American Headache Society (AHS) Virtual Annual Scientific Meeting which began June 13.
  • Additional abstracts examine disability outcome measurements from pooled analyses of three AJOVY Phase III trials FOCUS, HALO-Episodic Migraine, and HALO-Chronic Migraine.
  • We are committed to advancing the understanding of the AJOVY patient experience by continuing to examine patients with difficult-to-treat migraine.
  • AJOVY can be administered in office by a healthcare professional or at home by a patient or caregiver.

Antares Pharma to Present at the Raymond James Human Health Innovation Conference

Retrieved on: 
Thursday, June 11, 2020
Drugs, Receptor agonists, Androstanes, RTT, Organic compounds, Ketones, Testosterone enanthate, Sumatriptan, Teva Pharmaceutical Industries, Testosterone, Injection, Triptan

EWING, N.J., June 11, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the Company), today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Raymond James Human Health Innovation Conference on Thursday, June 18, 2020 at 9:40 a.m. Eastern Time.

Key Points: 
  • EWING, N.J., June 11, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the Company), today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Raymond James Human Health Innovation Conference on Thursday, June 18, 2020 at 9:40 a.m. Eastern Time.
  • A live webcast of the presentation will be available under the For Investors section of the Antares website, www.antarespharma.com .
  • Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug delivery auto injector technology.
  • Antares Pharmas FDA approved products include XYOSTED (testosterone enanthate) injection, OTREXUP (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva.